Soluble Mesothelin Related Peptides (MESOMARK®)


The MESOMARK test is the first in vitro diagnostic test for patients with mesothelioma.

Mesothelioma is a rare form of cancer in which fluid accumulates in the lungs and chest cavity. Mesothelioma can also be found in the lining of the pleural cavity of the abdomen. It is primarily caused by work-related asbestos exposure, and it is estimated that 10,000 new cases are diagnosed each year among industrialized countries. Malignant mesothelioma is an extremely aggressive disease with a poor prognosis.

The MESOMARK assay is a manual enzyme-linked immunosorbent assay for the quantitative measurement of Soluble Mesothelin-Related Peptides (SMRP). SMRP is a biomarker that is released into the bloodstream by mesothelioma cells. SMRP can be elevated years before an actual diagnosis of mesothelioma is made. By measuring the amount of SMRP present in the bloodstream, the MESOMARK assay will help physicians routinely monitor individuals with the greatest risk of developing mesothelioma due to asbestos exposure.


The MESOMARK assay is an Enzyme-Linked Immunosorbent Assay (ELISA) for the quantitative measurement of Soluble Mesothelin-Related Peptides (SMRP) in human serum. The MESOMARK assay measures soluble molecules that are related to the mesothelin/Megakaryocyte Potentiating Factor (MPF) family of proteins and recognized by the monoclonal antibody OV569. The reactivity of OV569 is low for normal human tissues except for the mesothelium. Soluble members of the mesothelin/MPF family of proteins have been reported in the sera of patients with tumors of mesothelial origin.